XL 19p/19q del

Deletion Probe

Order Number
D-6019-100-OG
Package Size
100 µl
Labels
  
Chromosome
19

Description

XL 19p/19q del

XL 19p/19q del detects deletions in the long arm of chromosome 19. The orange labeled probe hybridizes to the GLTSCR1 and GLTSCR2 locus at 19q13. A green labeled probe hybridizes to a specific locus at 19p13 and functions as a reference probe.

This probe is intended for methanol/acetic-acid fixed cells and tissue sections.

Clinical Details

The 2016 ´World Health Organization Classification of Tumors of the Central Nervous System´(WHO 2016) combines, for the first time, histological features and molecular signatures for the definition of many tumor entities. Gliomas are a category of tumors of the brain and spinal cord starting in glia cells. Oligodendrogliomas are a subtype of gliomas accounting for up to 18% of all cases. According to the WHO 2016, the classification of an oligodendroglioma requires information about the isocitrate dehydrogenase mutation status and 1p/19q loss of heterozygosity (LOH). LOH of 19q can be detected in about 80% of oligodendroglial tumors and to a lower extend in mixed gliomas. Co-deletion of 1p/19q is a well-accepted prognostic biomarker in neuro-oncology. Patients suffering from anaplastic oligodendroglioma harboring 1p/19q deletion, generally have a good prognosis. Co-deletion of 1p/19q has also predictive character, the molecular status of 1p/19q is relevant for therapy decisions.

Clinical Applications

  • Solid Tumors (Solid Tumors)

Images

XL 19p/19q del

XL 19p/19q del hybridized to oligodendroglioma tissue. Loss of heterozygosity of 19q is indicated by the loss of one orange signal.

Expected Patterns

Expected Pattern 1

Normal Cell:
Two green (2G) and two orange (2O) signals.

Expected Pattern 2

Aberrant Cell (typical results):
Two green (2G) and one orange (1O) signal resulting from loss of one orange signal.

Literature

  • Reifenberger et al (1994) Am J Pathol 145:1175-1190
  • Louis et al (2016) Acta Neuropathol 131:803-820
  • Staedtke et al (2016) Trends Cancer 2:338-349

Downloads

Order Now or Request Assistance

Contact Us »

Contact MetaSystems directly or find your local MetaSystems partner.